Janelle R. Anderson

Janelle R. Anderson is the Chief Business Officer of F2G, a biopharmaceutical company. She is a seasoned professional with 20 years of experience in operational and dealmaking roles within the biopharmaceutical industry and venture capital funds.1

Career Highlights

Dr. Anderson's career is marked by significant achievements and diverse roles:

• Current Position: Chief Business Officer at F2G12
• Previous Roles:
  • Chief Strategy Officer at Century Therapeutics, a company she helped found1
  • Head of Finance for Biologics and Vaccines R&D at Merck1
  • Managing Director of MRL Ventures Fund, Merck's therapeutic-focused venture arm1
  • Managing Partner at CTI Life Sciences Fund1
  • Interim Chief Executive Officer at Access Scientific1

Education and Background

Janelle R. Anderson has a strong academic background in chemistry:

• BSc in Chemistry (honors) from McGill University1
• AM and PhD from the Department of Chemistry and Chemical Biology at Harvard University1

She began her professional career as a management consultant at the Boston Consulting Group.1

Achievements and Expertise

Dr. Anderson has demonstrated expertise in:

1. Dealmaking and partnerships in the biopharmaceutical sector
2. Venture capital and fund management
3. Strategic planning and execution in biotech startups
4. Financial management in R&D for large pharmaceutical companies

Her accomplishments include founding Century Therapeutics, securing its foundational technology, and acquiring Empirica Therapeutics.1

Current Responsibilities

As Chief Business Officer at F2G, Dr. Anderson likely plays a crucial role in:

• Developing business strategies
• Managing partnerships and collaborations
• Overseeing financial operations
• Driving growth and expansion initiatives

Additional Roles

Dr. Anderson serves as a Director on the boards of:

• Gardiner Healthcare Acquisitions Corp
• Jazz House Kids1

Janelle R. Anderson's diverse experience in both scientific and business aspects of the biopharmaceutical industry makes her a valuable asset to F2G and the broader biotech community.